The Malaria Vaccine (MalVax) Alliance

Accelerating the development of better vaccines for a malaria free future

INTRODUCING MALVAX

The Malaria Vaccine (MalVax) Alliance is a new global, independent collaboration accelerating the development of malaria vaccines.

The MalVax Alliance unites the malaria vaccine R&D community to drive evidence and innovation from lab to policy faster, so better vaccines reach the people who need them sooner. It coordinates action around shared priorities by:

Strengthening innovation and clinical investigation through shared frameworks

Improving the quality and comparability of research evidence

Accelerating the translation of that evidence into regulatory and policy decisions

MalVax 2027: The First Global Malaria Vaccine Alliance R&D Conference

Kuala Lumpur, Malaysia
31 January - 3 February 2027

THE OPPORTUNITY

Global coordination will accelerate impactful malaria vaccine development

Recent consultations across the malaria vaccine community have highlighted opportunities to address persistent challenges slowing the development of improved next-generation malaria vaccines. The areas identified include increasing coordination, harmonising clinical trial designs, supporting and improving data comparability, and supporting increased clarity and evidence for funding, policy, regulatory and implementation pathways.

Stakeholders agreed that an impartial and objective mechanism could help improve community coordination and alignment, accelerate and facilitate decision-making during product development, and help guide and accelerate the next phase of next-generation malaria vaccine innovation.

The MalVax Alliance was established in early 2026 in response to this call.The MalVax Alliance serves as an independent, global platform, uniting researchers, vaccine developers,funders, policymakers, regulators, and partners to working in malaria-endemic countries and internationally accelerate the development of effective, accessible, and affordable malaria vaccines.

Together, we are working to:

This is some text inside of a div block.

Share Science

Strengthen scientific exchange and shared knowledge across the community.

This is some text inside of a div block.
This is some text inside of a div block.

Break Bottlenecks

Coordinate expertise to address common research and development challenges.

This is some text inside of a div block.
This is some text inside of a div block.

Align Efforts

Improve comparability and support evidence generation across the ecosystem.

This is some text inside of a div block.

COMMITTEE

Executive Committee

The Executive Committee, assisted by a Support Unit at Bridges to Development, leads the work to build the foundations of an inclusive and effective MalVax Alliance:

This is some text inside of a div block.

Melissa Penny

Professor Fiona Stanley Chair in Child Health Research, The Kids Research Institute Australia, University of Western Australia (Australia)

This is some text inside of a div block.
This is some text inside of a div block.

Simon Draper

Professor of Vaccinology and Translational Medicine, University of Oxford (UK)

This is some text inside of a div block.
This is some text inside of a div block.

Katharine Collins

Senior Program Officer, Global Health R&D, Coefficient Giving (UK)

This is some text inside of a div block.

COMMITTEE

Advisory Group

The Advisory Group is composed of leaders drawn from across the malaria vaccine R&D community and related ecosystem. It provides strategic input and guidance to the Executive Committee, supporting early priority setting and governance design. This is an interim arrangement, in place until a permanent governance structure launches in 2027.

This is some text inside of a div block.

Peter Crompton

Senior Investigator, Malaria Infection Biology and Immunity Section, NIAID/DIR (USA)

This is some text inside of a div block.
This is some text inside of a div block.

Melissa Kapulu

Professor, Malaria Transmission & Human Infection Studies, KEMRI-Wellcome Trust Research Programme (Kenya)

This is some text inside of a div block.
This is some text inside of a div block.

Miriam K. Laufer

Global Clinical Franchise Leader, Sanofi (USA)

This is some text inside of a div block.
This is some text inside of a div block.

Abdisalan M. Noor

Executive Director, AHADI - Applied Health Analytics for Delivery and Innovation

This is some text inside of a div block.
This is some text inside of a div block.

Halidou Tinto

Director of Research in Parasitology, IRSS – Clinical Research Unit of Nanoro (Burkina Faso)

This is some text inside of a div block.
This is some text inside of a div block.

Nicola Viebig

Director of Research, European Vaccine Initiative (Germany)

This is some text inside of a div block.
This is some text inside of a div block.

Philip Welkhoff

Director, Malaria Program, Gates Foundation (USA)

This is some text inside of a div block.
This is some text inside of a div block.

Brandon Wilder

Associate Professor, Oregon Health & Science University (USA)

This is some text inside of a div block.
This is some text inside of a div block.

Lindsey Wu

Technical Officer, Malaria Vaccines, WHO (Switzerland)

This is some text inside of a div block.

WORKING GROUPS

MalVax Technical Working Groups

The Alliance's activities will be delivered initially through three Technical Working Groups:

Working Group 01

Endpoints & Trial Design

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod.

WG 1 Technical Scope
Working Group 02

Assays

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod.

WG2 Technical Scope
Working Group 03

Modelling

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod.

WG3 Technical Scope
Joint Working Group with WHO

WHO Technical Advisory Group (TAG) on malaria vaccines. Coming Soon.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod.

All MalVax Working Groups are governed by a shared Terms of Reference.

MalVax 2027: The First Global Malaria Vaccine Alliance R&D Conference

The First Global Malaria Vaccine (MalVax) Alliance R&D Conference will take place in Kuala Lumpur, Malaysia from 31 January to 3 February 2027, bringing together the international research and development (R&D) community to share evidence, strengthen collaboration, and accelerate progress towards next-generation malaria vaccines. It will also serve as a platform to share and collaborate on the newly launched MalVax Alliance Working Groups on clinical trial design and endpoints, assays, and modelling and share status of expected outputs.

CONFERENCE COMMITTEE

Scientific Conference Committee

With expertise spanning across the malaria vaccine R&D community, the MalVax Scientific Conference Committee (SCC) guides the scientific planning, abstract selection and delivery of this meeting. MalVax 2027 SCC members are:

Jake Baum
UNSW Sydney (Australia)
Rhea Longley
WEHI (Australia)
Melissa Kapulu
KEMRI-Wellcome Trust Research Programme (Kenya)
Catherine Mkindi
Ifakara Health Institute (Tanzania)
Muhammed Afolabi
London School of Hygiene & Tropical Medicine (UK)
Claude Muvunyi
Rwanda Biomedical Center (Rwanda)
Linda Amoah
Noguchi Memorial Institute for Medical Research (Ghana)
Benjamin Mordmüller
Radboud University Medical Center (Netherlands)
Joe Challenger
Imperial College London (UK)
Fitsum Tadesse
Armauer Hansen Research Institute (Ethiopia)
Carlota Dobaño
ISGlobal (Spain)
Eizo Takashima
Ehime University (Japan)
Denise Doolan
University of Queensland (Australia)
Josh Tan
National Institute for Health (USA)
Danika Hill
Monash University (Australia)
Laty Gaye Thiam
Institut Pasteur de Dakar (Senegal)
Jean-Philippe Julien
Hospital for Sick Children Research Institute (Canada)
Alfred Tiono
Groupe de Recherche Action en Santé (Burkina Faso)
Simon Kariuki
Kenya Medical Research Institute (Kenya)
Ashley Vaughan
Seattle Children's Research Institute (USA)
Epke Le Rutte
The Kids Research Institute Australia (Australia)
Barney Williams
University of Oxford (UK)

REGISTRATION

Registration is now open!

Registration includes:

  • All Conference Sessions
  • Conference Catering (morning tea, lunch and afternoon tea)
  • Welcome and Evening Receptions

Low- and middle income country (LMIC) rate

Student / Post-doc rate
$50
Professional
$150

Standard rate

Student / Post-doc rate
$150
Professional
$400

CALL FOR ABSTRACTS

Abstract submissions are now open!

Researchers of all career stages and partners from across the malaria vaccine R&D community are invited to submit their latest scientific work, including original research, new data, and innovations supporting the acceleration of malaria vaccine development.

Pre-Erythrocytic Vaccines (PEV)
Vaccine Immunology (e.g. vaccine immunogenicity, immune monitoring, surrogate markers)
Blood-Stage Vaccines (BSV)
Modelling related to any of the above
Transmission-Blocking Vaccines (TBV)
Lessons for clinical development (e.g. from social or implementation sciences)
Multi-Stage Vaccines
Adjuvants
Preclinical and Clinical Development
Vaccine approval and implementation as they inform R&D
Universities and academic institutions
Pharmaceutical and biotechnology companies
Research institutes
Funders (philanthropy, foundations, bilateral donors)
Ministries of Health and regulatory authorities
WHO and other multilateral organizations (e.g. UN agencies, Gavi, Global Fund)
Implementing and technical partners (e.g. NGOs)
Care providers

Submission Requirements

Abstracts must be written in clear scientific English and should not exceed 275 words. Full details will be available on the submission portal.

Plasmodium falciparum vaccines will be the primary focus of the meeting, but abstracts covering Plasmodium vivax or multi-Plasmodium species vaccines, vaccines targeting malaria in pregnancy, or monoclonal antibodies are also welcomed for submission and consideration by the Scientific Conference Committee (SCC).

Timeline

July 22, 2026
ABSTRACT CALL ISSUED
July 31, 2026
REGISTRATION AND ABSTRACT SUBMISSIONS OPEN
September 7, 2026
ABSTRACT DEADLINE
Mid October, 2026
ABSTRACT DECISIONS COMMUNICATED

PROGRAMME

Shaped by the science submitted to this conference

Our Programme will be shaped by the science abstracts submitted to this conference: aiming to represent all voices. The programme runs over three and a half days:

Day 1
Opening plenary (afternoon), followed by official MalVax launch and welcome reception .
SUNDAY, 31 JANUARY 2027
Day 2
Scientific and poster sessions, and planned Working Group interactions.
MONDAY, 1 FEBRUARY 2027
Day 3
Scientific and poster sessions, and planned Working Group interactions.
TUESDAY, 2 FEBRUARY 2027
Day 4
Scientific sessions and closing reception.
WEDNESDAY, 3 FEBRUARY 2027

Meet in Malaysia

TRAVEL & VENUE

Planning your trip

The conference will take place in Kuala Lumpur, 31 January to 3 February 2027.

The conference was originally planned to be held in Kigali, Rwanda. In light of the evolving Ebola outbreak in the region, the organisers completed a review of alternative venues across Africa, Europe, and Asia. The review prioritised ease of participation for colleagues from Africa and other countries where visa access has historically been a barrier, together with cancellation risk, flight connectivity from all regions, and suitable meeting infrastructure.

Kuala Lumpur offers visa-free entry or straightforward online eVisas for most participants, strong flight connectivity avoiding Middle East transit hubs, and world-class meeting infrastructure. Travel and accommodation support will be available to encourage broad participation from colleagues in low- and middle-income countries, with further details shared at registration. As the meeting will not be virtual, selected abstracts will require in person attendance.

Planning ahead ensures a smoother journey. Review the latest requirements before booking your travel.

We anticipate that visas to travel to Malaysia will be straightforward. Nonetheless, all conference delegates are responsible for ensuring they meet Malaysia's entry requirements before travelling. Participants are encouraged to confirm the requirements applicable to their nationality before making travel arrangements. Please note that conference organisers will provide a letter of conference registration confirmation to support visa applications.

Malaysia eVISA Portal

Visa Requirements by Country

TRAVEL SUPPORT

Travel Support Application

MalVax 2027 registrants from low- and middle-income countries (LMICs) who require financial support to attend may apply for travel support. Please note that a limited number of grants is available.

The financial support is intended to offset travel costs associated with attending the conference, so finances are not a barrier to participation.

FUNDER

Coefficient Giving

The establishment of the MalVax Alliance and the initiation of the inaugural conference has been made possible thanks to support from Coefficient Giving.

Sponsorship interest

Organisations interested in sponsoring the conference are encouraged to reach out to the MalVax Support Unit at Bridges to Development:

info@malvax.org

STAY CONNECTED

Stay Informed about MalVax

If you have not done so yet, please sign up via our short engagment survey using the link below

For questions about MalVax or the inaugural conference, please contact the Support Unit at Bridges to Development

info@malvax.org

Social Media

We encourage interested partners to follow and use the hashtag #MalVax2027 on social media.